Cyndi Green, PhD, MBA, is currently the Lead for Search and Innovation in Worldwide Business Development at Pfizer in Manhattan. Cyndi has broad biotech and pharma experience in drug development, licensing, business strategy, commercialization, venture capital, alliance management and genomics. In her current role, she has responsibility for partnering marketed and clinical stage assets, technologies and diagnostics, primarily in vaccines and anti-infectives. She is the therapeutic area lead for company outreach, technical due diligence, coordinating activities across multifunctional teams to determine program quality, likelihood of approval and overall valuation. During her tenure at Pfizer, Cyndi has had an integral role in the acquisition of AZ’s small molecule antibiotics portfolio, GSK’s and Baxter’s marketed vaccines, in the out-licensing of sutezolid to Sequella, in the formation of incubator newco RGo Biosciences, and in the formation of the Pfizer-GSK HIV joint venture, ViiV Healthcare.
Before coming to Pfizer in 2003, she spent over 5 years at biotechnology company CuraGen Corporation. Cyndi has undergraduate degrees from Alfred State College and SUNY Fredonia, a masters and doctorate in molecular biology from SUNY Buffalo, an MBA from Rensselaer Polytechnic Institute, and completed executive education in Private Equity and Venture Capital at Harvard Business School. She was a postdoc at Yale University School of Medicine where she was a Howard Hughes Medical Institute and an Arthritis Research Foundation Fellow. Cyndi is currently on the Executive Leadership Board of Directors for NewYorkBIO and actively supports a number of local biotechnology and healthcare initiatives.